Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
imPaCT-PRO: Tinzaparin Thromboprophylaxis in Advanced Pancreatic Cancer
2021-005530-42Phase 3Active
- Sponsor
- Institute of Molecular Medicine and Biomedical Research
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tinzaparin in pancreatic cancer (PC) and venous thromboembolism (VTE) (2 arms), sponsored by Institute of Molecular Medicine and Biomedical Research. Primary endpoint: Progression-free survival with tinzaparin thromboprophylaxis vs no prophylaxis. Started Nov 2021; status: active.
02
Drugs
tinzaparin
03
Conditions
pancreatic cancer (PC)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2021-005530-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005530-42.